Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase II multicentre trial, 80 chemotherapy-naive patients with metastatic melanoma received a total of 218 cycles of treatment. The response rate showed one complete and three partial responses of median duration six months (range 3-9.1). Toxicity was moderate, mostly haematological (neutropenia grade 4 in 16%, grade 3 in 3%). There were no significant problems with hypertension or other non-haematological toxicities.
Author(s): Smyth, J., Boneterre, M. E., Schellens, J., Calvert, A. H., Greim, G., Wanders, J., Hanauske, A.
Publication type: Article
Publication status: Published
Journal: Annals of Oncology
Year: 2001
Volume: 12
Issue: 4
Pages: 509-511
ISSN (print): 0923-7534
ISSN (electronic): 1569-8041
URL: http://annonc.oxfordjournals.org/cgi/reprint/12/4/509
Notes: EORTC Early Clinical Studies Group
